Search
Pentastarch
go.drugbank.com/drugs/DB09111ApprovedWithdrawnPentastarch is an artificial colloid (hydroxyethyl starch derivative). Pentastarch is characterized by presenting five hydroxyethyl groups, which signifies an approximate 50% hydroxyethylation. … When administered, pentastarch remains mainly in the circulatory system and hence, it is considered a plasma expander.
Categories: Compounds used in a research, industrial, or household settingElacestrant
go.drugbank.com/drugs/DB06374ApprovedInvestigational[L44918,L44948] It received a similar approval in the EU in September 2023. … of a SERD represents a therapeutic approach for the treatment of endocrine-resistant breast cancers.
Categories: Estrogens, Non-SteroidalSynonyms: (2R)-2-(2-(ethyl-((4-(2-(ethylamino)ethyl)phenyl)methyl)amino)-4-methoxy-phenyl)tetralin-6-ol, (6R)-6-(2-(ethyl((4-(2- (ethylamino)ethyl)phenyl)methyl)amino)-4-methoxyphenyl)- 5,6,7,8-tetrahydronaphthalen-2-olPemigatinib
go.drugbank.com/drugs/DB15102ApprovedInvestigationalWith increasing research on the pathogenesis of cholangiocarcinoma and potential therapeutic targets for anticancer drug treatment, recent studies show that up to 45% of patients with intrahepatic cholangiocarcinoma … [A198963] The FDA-approved indication for pemigatinib was granted under accelerated approval based on the overall response rate and duration of response in pre-marketing clinical trials.
Almitrine
go.drugbank.com/drugs/DB01430ApprovedAlmitrine is a respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. … It is used in the treatment of chronic obstructive pulmonary disease.
Categories: Compounds used in a research, industrial, or household settingTetraferric tricitrate decahydrate
go.drugbank.com/drugs/DB14520ApprovedInvestigational[A25965] Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014.[L9926] … Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease.
Categories: Drugs for Treatment of Hyperkalemia and HyperphosphatemiaEsmolol
go.drugbank.com/drugs/DB00187ApprovedInvestigationalWithdrawnIt has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. … It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions.
Products: Esmolol Hydrochloride in Water, Esmolol Hydrochloride In Sodium ChlorideRutin
go.drugbank.com/drugs/DB01698ApprovedInvestigationalA flavonol glycoside found in many plants, including buckwheat; tobacco; forsythia; hydrangea; viola, etc. It has been used therapeutically to decrease capillary fragility.
Synonyms: 3-[[6-O-(6-Deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy]-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-oneMixtures: Rose Hips 500plus Nu Life, Nutriforte Non-Acidic Vitamin C 1000 mg with BioflavonoidsAlanine
go.drugbank.com/drugs/DB00160ApprovedInvestigationalNutraceuticalAlanine is a non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. … It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system.
Mixtures: SOLUCION DP-AMINE, TRAVASOL PLUS 15% LIBRE DE BISULFITOPravastatin
go.drugbank.com/drugs/DB00175ApprovedInvestigationalPravastatin is the 6-alpha-hydroxy acid form of [mevastatin].[T303] Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. … The manufacturing process is followed by the hydrolysis of the lactone group and the biological hydroxylation with _Streptomyces carbophilus_ to introduce the allylic 6-alcohol group.[T239]
Products: Nu-pravastatin TabletsViltolarsen
go.drugbank.com/drugs/DB15005ApprovedInvestigationalis contingent on further verification in confirmatory trials. … [A218176] Viltolarsen was granted accelerated FDA approval on August 12, 2020, based on data showing an increase in dystrophin levels in skeletal muscle of patients treated with viltolarsen; this approval